Merck Serono opens doors at R&D shop in Beijing

As the world's drugmakers angle for their share of the fast-growing Chinese market, Merck KGaA's Serono unit has started operations this week at its R&D facility in Beijing, China Daily reported. The main focus of the research shop will be individualized treatments for cancer and other diseases, according to the Chinese newspaper.

The facility has opened nearly two years after the company announced it would pour $225 million into the operation and employ hundreds of workers. Complementing its research hubs in the U.S., Germany and Switzerland, the Beijing lab will focus on drugs for cancer, neurodegenerative disorders, autoimmune and inflammatory diseases that are tailored for specific patients based on their genetics and other biological traits, according to the article.

While making research investments in the country, Merck Serono is keeping a close eye on the growing pharmaceutical market in China. Wayne Paterson, the company's executive VP of emerging markets, said he expects China to become the No. 2 market for the company after the U.S. within 6 years.

- see the article in China Daily

Suggested Articles

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.

The FDA has handed Scholar Rock a rare pediatric disease designation voucher, which can allow the biotech a speedy review of its SMA med.

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.